Overview

Efficacy and Tolerability CVI (A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial (CVI)

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:
0

Participant gender:

Summary

To determine efficacy and tolerability of Antistax 360 mg tablets in chronic venous insufficiency linked to edema (swelling) and subjective symptoms

Phase:

Phase 3

Details

Lead Sponsor:

Boehringer Ingelheim